The Technical Analyst
Sellas Life Sciences [SLS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sellas Life Sciences Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.32% $1.540
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 86.65 mill |
| EPS: | -1.340 |
| P/E: | -1.150 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 56.27 mill |
| Avg Daily Volume: | 1.407 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.150 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.20x |
| Company: PE -1.150 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0621 (-95.97%) $-1.478 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.417 - 1.663 ( +/- 7.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-22 | Stergiou Angelos M. | Buy | 159 000 | Common Stock |
| 2024-01-22 | Stergiou Angelos M. | Buy | 238 500 | Stock Option (Right to Buy) |
| 2024-01-22 | Scheinberg David A | Buy | 6 000 | Common Stock |
| 2024-01-22 | Scheinberg David A | Buy | 10 000 | Stock Option (Right to Buy) |
| 2024-01-22 | Wood Barbara A | Buy | 35 000 | Common Stock |
| INSIDER POWER |
|---|
| 95.64 |
| Last 98 transactions |
| Buy: 3 194 450 | Sell: 76 679 |
Forecast:
16:00 - $1.520
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.520
Forecast 2: 16:00 - $1.520
Forecast 3: 16:00 - $1.520
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.540 (1.32% ) |
| Volume | 1.787 mill |
| Avg. Vol. | 1.407 mill |
| % of Avg. Vol | 127.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Sellas Life Sciences Reports Full Year 2023 Financial Results And Provides Corporate Update
New york, march 28, 2024 (globe newswire) -- sellas life sciences group, inc. (nasdaq: sls) (“sellas'' or the “company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended december 31, 2023, and provided a corporate update.
2024-03-26 07:35:00 - Press Release
Sellas Announces Positive Topline Data From The Phase 2a Study Of Sls009 In R/r Aml And Provides Steering Committee Update On Phase 3 Regal Study
- phase 3 regal study of gps in aml: enrollment completed; steering committee guided interim analysis imminent; idmc now scheduled in late april -
2024-03-19 16:05:00 - Press Release
Sellas Life Sciences Group Announces Closing Of $20 Million Registered Direct Offering And Concurrent Private Placement Priced At-the-market Under Nasdaq Rules
New york, march 19, 2024 (globe newswire) -- sellas life sciences group, inc. (nasdaq: sls) (“sellas'' or the “company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the closing of its previously announced registered direct offering of 13,029,316 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 13,029,316 shares of common stock issued in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.535 per share and accompanying warrant, priced at-the-market under nasdaq rules...
2024-03-19 08:47:00 - Press Release
Sellas Life Sciences To Host Corporate Update Call On March 26, 2024, At 8:15 Am Et
- update on the phase 3 regal clinical trial of gps in acute myeloid leukemia (aml) - - update on the phase 2a clinical trial of sls009 in relapsed/refractory aml, including topline data - new york, march 19, 2024 (globe newswire) -- sellas life sciences group, inc. (nasdaq: sls) (“sellas'' or the “company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on march 26, 2024, at 8:15 am et. angelos stergiou, md, scd h.c.
2024-03-15 09:00:00 - Press Release
Sellas Life Sciences Group Announces $20 Million Registered Direct Offering And Concurrent Private Placement Priced At-the-market Under Nasdaq Rules
New york, march 15, 2024 (globe newswire) -- sellas life sciences group, inc. (nasdaq: sls) (“sellas'' or the “company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into definitive agreements with two existing institutional investors for the purchase and sale of 13,029,316 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to an aggregate of 13,029,316 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1...
Latest News
2024-04-19 13:49:43 - Seeking Alpha
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen, which is overexpressed in AML patients. The AML market size is estimated to be $3.1 billion. The upcoming interim readout of the GPS phase 3 clinical trial in April could significantly impact the valuation of the drug, with a successful trial potentially increasing its value to $1.5B.
2024-01-25 08:45:00 - GlobeNewsWire
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.
2024-01-10 12:47:08 - Zacks Investment Research
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
2024-01-04 08:41:42 - InvestorPlace
Why Is Sellas Life Sciences (SLS) Stock Down 25% Today?
Sellas Life Sciences (NASDAQ: SLS ) stock is taking a beating on Thursday after the late-stage clinical biopharmaceutical company announced a proposed public share offering. Sellas Life Sciences has yet to release the finer details of the public offering.
2023-10-17 08:45:00 - GlobeNewsWire
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the topline clinical data from the final analysis of the Phase 1/2 clinical trial of galinpepimut-S (GPS) in combination with pembrolizumab (Keytruda®) in Wilms' tumor-1 (WT1)-positive platinum-resistant ovarian cancer (NCT03761914) will be presented at an e-Poster session at the 2023 International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place November 5-7, 2023, in Seoul, South Korea.
2023-09-18 16:19:00 - GlobeNewsWire
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, and members of the SELLAS management team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference, taking place in New York, NY, from September 26-28, 2023.
2023-06-13 08:30:00 - GlobeNewsWire
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, has been invited to participate in a fireside chat at the Maxim Group Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, taking place June 20-22, 2023.
2023-05-25 17:05:00 - GlobeNewsWire
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for the Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago.
2023-02-24 08:42:00 - Market Watch
Sellas Life Sciences raises $20 million from public offering of stock, warrants
Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which is focused on cancer treatments, plummeted 43.1% in premarket trading, after the offering was initially announced without terms late Thursday.
2023-02-24 08:29:26 - InvestorPlace
Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?
SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life Sciences intends to offer up shares of SLS stock, as well as warrants to purchase shares of the stock.